ReviewRambam Maimonides medical journal2020
Medical Cannabis in Children.
Review in Rambam Maimonides medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Cannabinoids for Medical Purposes in Children: A Living Systematic Review.Acta paediatrica (Oslo, Norway : 1992) · 2025Pooled it
- Use of Medical Cannabis in Patients with Gilles de la Tourette's Syndrome in a Real-World Setting.Cannabis and cannabinoid research · 2024Trial
- Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study.Children (Basel, Switzerland) · 2025Article
- Part 1: Evaluation of Pediatric Cannabis-Drug Interaction Reports.Pharmacology research & perspectives · 2025Review
- Cannabidiol potentiates phenobarbital effects in the control of pentylenetetrazole (PTZ)-induced epileptic seizures in neonate rats.Frontiers in pediatrics · 2025Article
- Cannabinoids in Integumentary Wound Care: A Systematic Review of Emerging Preclinical and Clinical Evidence.Pharmaceutics · 2024Review
- The Use of Compounds Derived fromInternational journal of molecular sciences · 2024Review
- CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.Pharmaceutics · 2024Review
- Cannabis and children: risk mitigation strategies for edibles.Frontiers in psychiatry · 2024Review
- Advances in the Treatment of Autism Spectrum Disorder: Current and Promising Strategies.Current medicinal chemistry · 2024Review
- Prescription Practices of Cannabinoids in Children with Cerebral Palsy Worldwide-A Survey of the Swiss Cerebral Palsy Registry.Children (Basel, Switzerland) · 2023Article
- Long-Term Treatment with Cannabidiol-EnrichedInternational journal of molecular sciences · 2023Article
- Medical cannabis in schools: The experiences of caregivers.Paediatrics & child health · 2023Article
- Medical cannabis in schools: A qualitative study on the experiences of clinicians.Paediatrics & child health · 2023Article
- How to Make the Unpredictable Foreseeable? Effective Forms of Assistance for Children with Autism Spectrum Disorder (ASD) during the COVID-19 Pandemic.Diagnostics (Basel, Switzerland) · 2023Review
- Acute cannabidiol treatment enhances social interaction in adult male mice.Advances in drug and alcohol research · 2023Article
- Utilisation of QSPR ODT modelling and odour vector modelling to predict Cannabis sativa odour.PloS one · 2023Article
- The role of cannabinoids in neurodevelopmental disorders of children and adolescents.Revista de neurologia · 2022Review
- Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders.Biomedicines · 2022Review
- Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of medical cannabis in children is rapidly growing. While robust evidence currently exists only for pure cannabidiol (CBD) to treat specific types of refractory epilepsy, in most cases, artisanal strains of CBD-rich medical cannabis are being used to treat children with various types of refractory epilepsy or irritability associated with autism spectrum disorder (ASD). Other common pediatric disorders that are being considered for cannabis treatment are Tourette syndrome and spasticity. As recreational cannabis use during youth is associated with serious adverse events and medical cannabis use is believed to have a relatively high placebo effect, decisions to use medical cannabis during childhood and adolescence should be made with caution and based on evidence. This review summarizes the current evidence for safety, tolerability, and efficacy of medical cannabis in children with epilepsy and in children with ASD. The main risks associated with use of Δ9-tetrahydrocannabinol (THC) and CBD in the pediatric population are described, as well as the debate regarding the use of whole-plant extract to retain a possible "entourage effect" as opposed to pure cannabinoids that are more standardized and reproducible.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.